Loading...
Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Plummer, R Arkenau, T Melear, J Redfern, C Spira, A Chung, K Haddad, T Ramalingam, S Wesolowski, R
Plummer, R
Arkenau, T
Melear, J
Redfern, C
Spira, A
Chung, K
Haddad, T
Ramalingam, S
Wesolowski, R
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 91.36 KB
Keywords
Type
Meetings and Proceedings
Citation
Plummer R, Cook N, Arkenau T, Melear J, Redfern C, Spira AI, et al. 1437P Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2018;29(suppl_8):519.